Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 Oct 5;22(2):834–848. doi: 10.1111/jcmm.13365

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2017 The Authors. Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine.

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Neurite degeneration is reduced by TAT‐MTScs‐FXN treatment. (A) Histogram showing the significant decreased percentage of neurite degeneration (measured as described in Materials and methods) produced by TAT‐MTScs‐FXN treatment using 7 μg/ml after 12 hrs compared to untreated cells. Error bars represent mean ± S.D., n = 4. (B) Representative images of 5‐day cultures of Scr, Fxn1 and Fxn2 treated with 7 μg/ml TAT‐MTScs‐FXN or vehicle solution 12 hrs after lentiviral transduction. Note the decrease in neurite aggregates (indicated by arrows) in treated cells (lower panels) compared with untreated cultures (upper panels). (C) Histogram showing the significant decreased percentage of neurite degeneration (measured as described in Materials and methods) produced by TAT‐MTScs‐FXN treatment (using 1 μg/ml, 3 μg/ml and 7 μg/ml) compared to untreated cells. Error bars represent mean ± S.D., n = 4.